Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Guanfacine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.51 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.51 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guanfacine SCHEMBL1173133 | 0.98 | ADRA2A (0.53) | KMT2AAKR1B1ADRA2AMAPK1MEN1 | |
| Guanfacine SCHEMBL41681 | 0.98 | ADRA2A (0.53) | KMT2AAKR1B1ADRA2AMAPK1MEN1 | |
| Guanfacine SCHEMBL438188 | 0.97 | AKR1B1 (0.53) | KMT2AAKR1B1ADRA2AMAPK1MEN1 | |
| Guanfacine SCHEMBL5539292 | 0.94 | KMT2A (0.49) | KMT2AAKR1B1ADRA2AMAPK1MEN1 | |
| Guanfacine SCHEMBL790727 | 0.90 | AKR1B1 (0.46) | KMT2AAKR1B1ADRA2AMAPK1MEN1 | |
| Guanfacine SCHEMBL20897969 | 0.90 | AKR1B1 (0.46) | KMT2AAKR1B1ADRA2AMAPK1MEN1 | |
| SCHEMBL20909489 | 0.89 | P2RX7 (0.47) | KMT2AAKR1B1ADRA2AMAPK1MEN1 | |
| Guanfacine SCHEMBL436700 | 0.89 | AKR1B1 (0.45) | KMT2AAKR1B1ADRA2AMAPK1MEN1 | |
| Guanfacine SCHEMBL10275259 | 0.89 | KMT2A (0.44) | KMT2AAKR1B1ADRA2AMAPK1MEN1 | |
| Guanfacine SCHEMBL439673 | 0.87 | KMT2A (0.43) | KMT2AAKR1B1ADRA2AMAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 12490 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3934622-B1 | DELAYED RELEASE METHYLPHENIDATE COMPOSITIONS | AMNEAL COMPLEX PRODUCTS RES LLC (US) | 2026-05-06 | — | — | EP | claimed |
| WO-2026090360-A1 | FUSED PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, HEARING LOSS, AND MENIERE'S DISEASE | OVID THERAPEUTICS INC. (US) | 2026-04-30 | — | — | WO | claimed |
| US-20260115163-A1 | NOVEL TREATMENTS | 3Z EHF (IS) | 2026-04-30 | — | — | US | claimed |
| US-20260108529-A1 | FUSED AMINO PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, ACUTE SENSORINEURAL HEARING LOSS, AGE-RELATED HEARING LOSS, AND MENIERE'S DISEASE | OVID THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | claimed |
| EP-4719368-A1 | INJECTABLE GUANFACINE FORMULATIONS AND METHODS | Cumberland Pharmaceuticals Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| EP-4712996-A1 | HIP/PAP PROTEIN OR A DERIVATIVE THEREOF FOR TREATING A COGNITIVE DISORDER ASSOCIATED WITH ANXIETY DISORDER | THE HEALTHY AGING COMPANY (FR) | 2026-03-25 | — | — | EP | claimed |
| US-20260076953-A1 | METHODS OF DIAGNOSING AND TREATING ADHD IN BIOMARKER POSITIVE SUBJECTS | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2026-03-19 | — | — | US | claimed |
| EP-4704826-A1 | COMPOSITIONS AND METHODS FOR TREATING POST-TRAUMATIC STRESS DISORDER | Yale University (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4704839-A2 | IMIDAZOLE CONTAINING COMPOUNDS, DERIVATIVES THEREFORE, AND USES THEREOF | ALPHERABIO LLC (US) | 2026-03-11 | — | — | EP | claimed |
| CN-121570440-A | High-water permeability and high-adhesion pressure-sensitive adhesive patch matrix and preparation method and application thereof | 沈阳药科大学 | 2026-02-27 | — | — | CN | claimed |
| EP-0184910-A2 | Device for controlled release drug delivery | HERCON LABORATORIES CORPORATION (US) | 1986-06-18 | — | — | EP | claimed |
| EP-0170193-A2 | Feedstuff additive for the growth promoting of agricultural useful animals | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 1986-02-05 | — | — | EP | claimed |
| EP-0164320-A1 | Pharmaceutical preparations for spinal analgesia containing guanfacine, and method for their preparation | Astra Läkemedel Aktiebolag (SE) | 1985-12-11 | — | — | EP | claimed |
| EP-0025269-B1 | ANTI-DIARRHOEA VETERINARY COMPOSITION | BEECHAM GROUP PLC (GB) | 1985-11-13 | — | — | EP | claimed |
| US-4404226-A | NEUROLEPTIC AGENTS | SANDOZ LTD. (CH) | 1983-09-13 | — | — | US | claimed |
| EP-0086428-A1 | Antidiarrhoea veterinary composition, its production and oral doser containing it | BEECHAM GROUP PLC (GB) | 1983-08-24 | — | — | EP | claimed |
| US-4380550-A | Guanfacine in treating opiate addiction | SANDOZ LTD. (CH) | 1983-04-19 | — | — | US | claimed |
| US-4152435-A | Compositions and methods to treat hypertension comprising a pyridazine and N-amidino-2-(2,6-dichlorophenyl) acetamide | SANDOZ LTD. (CH) | 1979-05-01 | — | — | US | claimed |
| US-4122190-A | Treating acromegaly | SANDOZ LTD. (CH) | 1978-10-24 | — | — | US | claimed |
| US-4046917-A | 2,6-DICHLOROPHENYL-ACETYLGUANIDINE | SANDOZ LTD. (CH) | 1977-09-06 | — | — | US | claimed |